Gland Pharma introduced on Wednesday, 30 April, that it had obtained approval from the US Meals and Drug Administration (USFDA) for its Abbreviated New Drug Software (ANDA) for latanoprostene bunod ophthalmic answer, 0.024%.
The authorized product is each bioequivalent and therapeutically equal to VYZULTA Ophthalmic Answer, 0.024%, developed by Bausch and Lomb, Inc.
This treatment is prescribed to decrease intraocular stress (IOP) in sufferers recognized with open-angle glaucoma or ocular hypertension. Open-angle glaucoma is probably the most prevalent type of glaucoma, a situation that may injury the optic nerve attributable to elevated eye stress.
Gland Pharma holds the unique First-to-File (FTF) standing for this drug, granting it 180 days of generic market exclusivity within the US.
As per IQVIA information, the product recorded US gross sales of roughly $171 million within the 12 months ending February.
Beforehand, Medical Dialogues reported that Gland Pharma had additionally obtained USFDA approval for Latanoprost Ophthalmic Answer, 0.005%, used for managing excessive eye stress in sufferers with comparable circumstances.
Based in 1978 in Hyderabad, Gland Pharma has advanced from a contract producer of small-volume parenterals to a globally acknowledged, injectable-focused pharmaceutical agency. The corporate serves over 60 international locations, together with the US, Europe, Canada, Australia, and India.
Working primarily on a business-to-business (B2B) mannequin, Gland Pharma specializes within the growth, manufacturing, and advertising of sterile injectable merchandise. Its intensive portfolio consists of vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology medicine, and ophthalmic options.
The way forward for investing is right here!
Unicorn Indicators leverages superior AI know-how to offer you highly effective market predictions and actionable inventory scans. Obtain the app right nowand 10x your buying and selling & investing journey!
